SCHEMBL8070199

SCHEMBL8070199

CC(C)Cn1c(=O)oc(=O)c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
TSHR P16473 3/20 0.53
HSD17B10 Q99714 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 3/20 0.47
HPGD P15428 2/20 0.47
TP53 P04637 1/20 0.46
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
HTT P42858 1/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
ELANE P08246 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSP90AA1 P07900 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6234103 0.85 ALDH1A1 (0.38) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL5308775 0.84 ALDH1A1 (0.55) SMN1; SMN2TSHRHSD17B10ALDH1A1KDM4E
SCHEMBL6305077 0.81 ALDH1A1 (0.59) TSHRHSD17B10TDP1L3MBTL1ALDH1A1
SCHEMBL20783160 0.80 MAPK1 (0.66) SMN1; SMN2TSHRL3MBTL1ALDH1A1HPGD
SCHEMBL24054671 0.79 DPP4 (0.42) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL30198037 0.79 DPP4 (0.42) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL24054939 0.79 DPP4 (0.42) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL5263281 0.79 PGR (0.50) TSHRHSD17B10TDP1ALDH1A1KDM4E
SCHEMBL9320462 0.78 POLB (0.43) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL6685738 0.78 ALDH1A1 (0.41) SMN1; SMN2TSHRHSD17B10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203003-A1 Notch Inhibitors and Uses Thereof STEMSYNERGY THERAPEUTICS, INC. 2023-06-29 US disclosed
US-20230203003-A1 Notch Inhibitors and Uses Thereof STEMSYNERGY THERAPEUTICS, INC. 2023-06-29 US disclosed
EP-4153576-A1 NOTCH INHIBITORS AND USES THEREOF StemSynergy Therapeutics, Inc. (US) 2023-03-29 EP disclosed
CN-115836056-A NOTCH inhibitors and uses thereof STEMSYNERGY疗法有限责任公司 2023-03-21 CN disclosed
WO-2021237112-A1 NOTCH INHIBITORS AND USES THEREOF STEMSYNERGY THERAPEUTICS, INC. (US) 2021-11-25 WO disclosed
US-9757369-B2 Heterocyclic GSK-3 allosteric modulators CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2017-09-12 US disclosed
US-20170196850-A1 Heterocyclic GSK-3 Allosteric Modulators CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2017-07-13 US disclosed
EP-2769720-B1 HETEROCYCLIC GSK-3 ALLOSTERIC MODULATORS CONSEJO SUPERIOR DE INVESTIG CIENTÍFICAS (CSIC) (ES) 2017-03-29 EP disclosed
US-9585879-B2 Heterocyclic GSK-3 allosteric modulators CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2017-03-07 US disclosed
US-20160113918-A1 Heterocyclic GSK-3 Allosteric Modulators CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2016-04-28 US disclosed
US-9193688-B2 Heterocyclic GSK-3 allosteric modulators CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2015-11-24 US disclosed
US-20150057311-A1 Heterocyclic GSK-3 Allosteric Modulators CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2015-02-26 US disclosed
EP-2769720-A1 HETEROCYCLIC GSK-3 ALLOSTERIC MODULATORS Consejo Superior De Investigaciones Científicas (CSIC) (ES) 2014-08-27 EP disclosed
JP-2000256333-A PRODUCTION OF 2-(ISOBUTYLAMINO)BENZYL ALCOHOL NIPPON CHEMIPHAR CO LTD 2000-09-19 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203003-A1 Notch Inhibitors and Uses Thereof NOTCH1, NOTCH2, NOTCH4 SMN1; SMN2 4659/4885TSHR 3942/4885HSD17B10 2619/4885
US-20170196850-A1 Heterocyclic GSK-3 Allosteric Modulators GSK3B, GSK3A, GSKIP SMN1; SMN2 1444/4885TSHR 3400/4885HSD17B10 1751/4885
US-20160113918-A1 Heterocyclic GSK-3 Allosteric Modulators GSK3B, GSK3A, GSKIP SMN1; SMN2 1444/4885TSHR 3400/4885HSD17B10 1751/4885
US-20150057311-A1 Heterocyclic GSK-3 Allosteric Modulators GSK3B, GSK3A, GSKIP SMN1; SMN2 1444/4885TSHR 3400/4885HSD17B10 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.